• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?

作者信息

Huang Weiyi, Chang Wenjun

机构信息

Department of Pharmacology, Shantou University Medical College, Shantou, Guangdong, China.

Department of Navy Environmental and Occupational Health, Naval Medical University, Shanghai, China.

出版信息

J Clin Transl Hepatol. 2022 Apr 28;10(2):179-180. doi: 10.14218/JCTH.2021.00553. Epub 2022 Mar 2.

DOI:10.14218/JCTH.2021.00553
PMID:35528986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9039706/
Abstract
摘要

相似文献

1
Newcastle Disease Virus/HK84: Next Potential Star for Targeted Immunotherapy of Hepatocellular Carcinoma?新城疫病毒/HK84：会是肝细胞癌靶向免疫治疗的下一颗潜在之星吗？
J Clin Transl Hepatol. 2022 Apr 28;10(2):179-180. doi: 10.14218/JCTH.2021.00553. Epub 2022 Mar 2.
2
Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling.野生型新城疫病毒HK84对与I型干扰素信号激活相关的肝细胞癌的溶瘤活性
J Clin Transl Hepatol. 2022 Apr 28;10(2):284-296. doi: 10.14218/JCTH.2021.00284. Epub 2021 Nov 19.
3
Therapeutic Use of Viruses: Newcastle Disease Virus HK84 Oncolytic Treatment for Hepatocellular Carcinoma.病毒的治疗用途：新城疫病毒HK84对肝细胞癌的溶瘤治疗
J Clin Transl Hepatol. 2022 Oct 28;10(5):783-785. doi: 10.14218/JCTH.2022.00229. Epub 2022 Jul 29.
4
Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.二氯乙酸盐通过靶向有氧糖酵解增强新城疫病毒介导的肝癌病毒免疫治疗。
Br J Cancer. 2020 Jan;122(1):111-120. doi: 10.1038/s41416-019-0639-7. Epub 2019 Dec 10.
5
Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma.氟达拉滨作为佐剂可增强新城疫病毒介导的肝癌抗肿瘤免疫。
Mol Ther Oncolytics. 2019 Mar 27;13:22-34. doi: 10.1016/j.omto.2019.03.004. eCollection 2019 Jun 28.
6
Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing.肝细胞癌靶向治疗与免疫治疗进展及新一代测序技术的应用
Ann Hepatol. 2022 Mar-Apr;27(2):100677. doi: 10.1016/j.aohep.2022.100677. Epub 2022 Jan 28.
7
Is there a role for immunotherapy in hepatocellular carcinoma?免疫疗法在肝细胞癌中是否有作用？
Dig Liver Dis. 2006 Apr;38(4):221-5. doi: 10.1016/j.dld.2005.12.004. Epub 2006 Feb 3.
8
Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.基因工程表达白细胞介素 2 的新城疫病毒是癌症免疫治疗的潜在药物候选物。
Immunol Lett. 2014 May-Jun;159(1-2):36-46. doi: 10.1016/j.imlet.2014.02.009. Epub 2014 Mar 7.
9
[Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].[肝细胞癌靶向治疗与免疫治疗的临床进展]
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
10
Steroidogenic acute regulatory (StAR)-directed immunotherapy protects against tumor growth of StAR-expressing Sp2-0 cells in a rodent adrenocortical carcinoma model.在啮齿动物肾上腺皮质癌模型中，类固醇生成急性调节蛋白（StAR）导向的免疫疗法可抑制表达StAR的Sp2-0细胞的肿瘤生长。
Endocrinology. 2004 Apr;145(4):1760-6. doi: 10.1210/en.2003-0983. Epub 2004 Jan 8.

引用本文的文献

1
Tumor organoids in cancer medicine: from model systems to natural compound screening.肿瘤类器官在癌症医学中的应用：从模型系统到天然化合物筛选
Pharm Biol. 2025 Dec;63(1):89-109. doi: 10.1080/13880209.2025.2458149. Epub 2025 Feb 1.
2
Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions.基于溶瘤病毒的肝细胞癌治疗：现状、静脉给药策略及新兴联合治疗方案
Asian J Pharm Sci. 2023 Jan;18(1):100771. doi: 10.1016/j.ajps.2022.100771. Epub 2022 Dec 29.

本文引用的文献

1
Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling.野生型新城疫病毒HK84对与I型干扰素信号激活相关的肝细胞癌的溶瘤活性
J Clin Transl Hepatol. 2022 Apr 28;10(2):284-296. doi: 10.14218/JCTH.2021.00284. Epub 2021 Nov 19.
2
Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.新城疫病毒抗肿瘤免疫治疗的研究进展。
Int J Med Sci. 2021 Mar 30;18(11):2294-2302. doi: 10.7150/ijms.59185. eCollection 2021.
3
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
4
Newcastle Disease Virus at the Forefront of Cancer Immunotherapy.新城疫病毒在癌症免疫治疗前沿领域
Cancers (Basel). 2020 Nov 28;12(12):3552. doi: 10.3390/cancers12123552.
5
Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.肝细胞癌的免疫治疗：2021年最新进展
Cancers (Basel). 2020 Oct 4;12(10):2859. doi: 10.3390/cancers12102859.
6
Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?溶瘤病毒：为实现治疗效果，它们必须有多“溶瘤”？
Oncoimmunology. 2019 Mar 28;8(6):e1581528. doi: 10.1080/2162402X.2019.1596006. eCollection 2019.
7
Hepatocellular Carcinoma.肝细胞癌
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
8
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.一项关于Pexa-Vec（JX-594）经瘤内注射用于不可切除原发性肝细胞癌患者的2期开放标签随机研究。
Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.
9
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.CTLA-4 阻断剂 tremelimumab 治疗肝细胞癌和慢性丙型肝炎患者的临床试验。
J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.
10
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.随机剂量探索性临床试验：溶瘤免疫治疗性痘苗病毒 JX-594 在肝癌中的应用。
Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.